<DOC>
<DOCNO>EP-0625986</DOCNO> 
<TEXT>
<INVENTION-TITLE>
OLIGOTHIONUCLEOTIDES
</INVENTION-TITLE>
<CLASSIFICATIONS>C07H2102	A61P3104	G01N3358	C07H2100	C12N1511	C12N1509	A61K3170	G01N33566	A61P3300	C12N1511	C12Q170	C12Q170	G01N3358	C07H2104	G01N33566	A61P3100	C07H2100	C12Q168	C12N1509	A61P3112	A61K3170	A61P3300	C12Q168	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07H	A61P	G01N	C07H	C12N	C12N	A61K	G01N	A61P	C12N	C12Q	C12Q	G01N	C07H	G01N	A61P	C07H	C12Q	C12N	A61P	A61K	A61P	C12Q	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07H21	A61P31	G01N33	C07H21	C12N15	C12N15	A61K31	G01N33	A61P33	C12N15	C12Q1	C12Q1	G01N33	C07H21	G01N33	A61P31	C07H21	C12Q1	C12N15	A61P31	A61K31	A61P33	C12Q1	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
CENTRE NAT RECH SCIENT
</APPLICANT-NAME>
<APPLICANT-NAME>
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BARASCUT JEAN-LOUIS
</INVENTOR-NAME>
<INVENTOR-NAME>
IMBACH JEAN-LOUIS
</INVENTOR-NAME>
<INVENTOR-NAME>
BARASCUT, JEAN-LOUIS
</INVENTOR-NAME>
<INVENTOR-NAME>
IMBACH, JEAN-LOUIS
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Chemical compounds consisting of an oligo-4'-thio-2'-deoxyribonucleotide 
or an oligo-4'-thioribonucleotide, 

characterized in that they comprise a 
concatenat
ion of 4'-thio-2'-deoxyribonucleotides or 4'-thioribonucleotides 
respectively, it being possible for 

the said concatenation to be optionally linked to an 
effector, especially a radical corresponding to an 

intercalating agent or a chemical or photoactivable 
radical, such as a radical carrying a functional group 

which reacts directly or indirectly with the nucleotide 
chains or a radical whose presence permits easy and 

sensitive detection. 
Chemical compounds according to Claim 1, consisting 
of an oligo-4'-thioribonucleotide or oligo-4'-thio-2'-deoxyribonucleotide, 

characterized in that they 
comprise a concatenation of 4'-thioribonucleotides or 

4'-thio-2'-deoxyribonucleotides respectively, not linked 
to an effector radical. 
Compounds according to Claim 1 or 2, characterized 
in that they correspond to the formula: 


 
in which: 


the B radicals may be identical or different and  
 

each represent a base of a nucleic acid optionally 
modified, activable and/or comprising an intercalating 

group and attached to the glycoside ring according to a 
non-natural alpha anomeric configuration; 
the X radicals may be identical or different and 
each represent an oxoanion O
-
, a thioanion S
-
, an alkyl 
group, an alkoxy group, a thioalkyl group, an alkyl or 

alkoxy radical substituted by a nitrogen-containing 
heterocycle or a -Y-Z group; 
R and R', which may be identical or different, 
each represent a hydrogen atom or a -Y-Z or Y'-Z' group; 
Y and Y', which are identical or different, each 
represent a straight or branched alkylene radical -alk- 

or a radical chosen from 

 
alk-O-alk 


 
with U = O, S or N 
E may have the same meanings as X except Y-Z or 
Y'-Z'; 
J represents a hydrogen atom or an hydroxyl 
group; 
Z and Z', which are identical or different, each 
represent OH or a radical corresponding to an effector, 

especially a radical corresponding to an intercalating 
agent or a radical carrying a functional group which 

reacts directly or indirectly with the nucleotide chains 
or a radical whose presence permits easy and sensitive 

detection 
n is an integer including 0; 
L represents an oxygen atom, a sulphur atom or a 
group -NH-. 
Compounds according to Claim 3, characterized in 
that Y and Y' represent a radical chosen from 


 
with U = O, S or N and n' is an integer especially from 

1 to 10. 
Compounds according to Claim 3, characterized in 
that L represents oxygen, R and R' represent a hydrogen 

atom and B represents a natural nucleic base. 
Compounds according to one of Claims 3 to 5, 
characterized in that the intercalating agent Z or Z' is 

chosen from polycyclic compounds having a planar configuration. 
Compounds according to Claim 6, characterized in 
that the intercalating agent Z or Z' is chosen from 

acridine and its derivatives, furocoumarin and its 
derivatives, daunomycin and the other derivatives of 

anthracycline, 1,10-phenanthroline, phenanthridine and 
its derivatives, proflavine, porphyrins, derivatives of 

dipyrido[1,2-a:3'-d]imidazole, ellipticine or ellipticinium 

and their derivatives and diazapyrene and 
derivatives. 
Compounds according to one of Claims 3 to 5, 
characterized in that the reactive chemical groups Z or 

Z' are chosen from ethylenediaminetetraacetic acid, 
diethylenetriaminepentaacetic acid, porphyrins, 

1,10-phenanthroline, 4-azidoacetophenone, ethylene-imine, 
beta-chloroethylamine, psoralen and their derivatives. 
Compounds according to one of Claims 3 to 8, 
characterized in that the B radical is a radical corresponding 

to thymine, adenine; 2-aminoadenine and its 
substituted derivatives, cytosine, guanine and its 

substituted derivatives, uracil, 5-bromouracil, 8-azidoadenine, 
7-deazaadenine, 7-deazaguanine, 4-azidocytosine, 

4-azidothymine and the derivatives of these bases comprising 
an intercalating group and/or a chemically or  

 
photochemically activable group. 
Compounds according to one of Claims 1 to 9, 
characterized in that they are oligothioribonucleotide 

compounds of formula I in which J = OH. 
Mixed oligomeric compounds characterized in that 
they consist of compounds according to one of Claims 1 to 

10 linked to DNA or RNA type oligonucleotides modified or 
otherwise at the level of the phosphate concatenation and 

in which the intracyclic heteroatom of the furanose ring 
of the nucleotides is oxygen. 
Mixed oligomeric compounds characterized in that 
they consist of a compound according to one of Claims 1 

to 10, especially of formula (I), comprising, at one or 
at each of its ends, a DNA or RNA type oligonucleotide 

sequence modified or not at the level of the 
phosphate concatenation, in which the heteroatom of the 

furanose ring of the nucleotides is oxygen. 
Mixed oligomeric compounds according to Claim 12, 
characterized in that they consist of an oligothioribonucleotide 

compound according to one of Claims 1 to 10, 
comprising a DNA type sequence modified or not at 

the level of the phosphate concatenation in whose 
nucleotides the heteroatom of the furanose ring of the 

nucleotides is oxygen. 
Mixed oligomeric compounds according to Claim 13, 
characterized in that the said DNA sequence, in which the 

heteroatom of the furanose ring is oxygen, is flanked by 
two sequences of the thioribonucleotide type. 
Process for the preparation of compounds according 
to one of Claims 1 to 13, characterized in that 

syntheses using phosphodiester, phosphotriester, 
phosphoramidite or hydrogen phosphonate are applied using 

4'-thionucleosides for oligothionucleotide sequences and 
in that the completely protected derivatives are prepared 

and that the protecting groups are removed. 
Process for the synthesis of the compounds 
without effector according to one of Claims 2 to 13, 

characterized in that to prepare the oligothionucleotide 
sequences, a supported synthesis is  

 
carried out according to the phosphoroamidite method 

comprising 

a protection in 3' and 5' of the starting 4'-thionucleotides 
or oligo-4'-thionucleotides with for 

example dimethoxytrityl in 5' and methyl diisopropylaminophosphoramidite 
in 3', 
the functionalization of a solid support incorporating 
a 4'-thionucleoside derivative by for example a 

succinyl linkage between the 3'-hydroxyl group of 
the 4'-thionucleoside derivative and an amino group 

of the solid support, 
the elongation of the oligothionucleotide chain in 
a synthesizing reactor, 
finally the detachment, deprotection and purification 
of the extended oligothionucleotide. 
Process for the synthesis of compounds incorporating 

an effector according to one of Claims 3 to 10, 
characterized in that there is used as starting material 

an oligothionucleotide without effector, or a mixed 
oligomer containing it, protected in 5', whose 3' OH end 

is reacted with an unprotected functional group of a 
difunctional arm whose second functional group is protected 

and after deprotection of the resulting product, 
the said product is linked to the effector by the second 

free functional group of the difunctional arm. 
Application of the compounds according to one of 
Claims 1 to 13, characterized in that the said compounds 

are used as hybridization probes or as purification 
components for given DNA or RNA sequences as single 

strand or as double helix for diagnostic or prognostic 
purposes. 
Application of the compounds according to one of 
Claims 1 to 13, characterized in that the compounds are 

used to detect mutations at the level of a DNA or an RNA. 
Application of the compounds according to one of 
Claims 1 to 13, characterized in that these compounds are 

used to carry out the specific blocking of cellular genes 
or of pathogenic agents chosen beforehand, such as 

viruses, bacteria or parasites, with the exclusion of the  
 

methods according to Art.52 (4)EPC. 
Application of a derivative according to one of 
Claims 1 to 13, to selectively block the expression of a 

gene either by hybridization or by selective cutting, or 
by chemical modification of the gene or of its messenger 

RNA of cellular, viral, bacterial or parasitic origin, 
with the exclusion of the methods according to Art.52 

(4)EPC. 
Application of a derivative according to one of 
Claims 1 to 13 to selectively block the expression of a 

viral RNA either by hybridization or by cutting or by 
chemical modification of the viral RNA or of its 

messenger RNA, with the exclusion of the methods according 
to Art.52 (4)EPC. 
Application of a derivative according to one of 
Claims 1 to 13, characterized in that it can be used as 

sequence-specific artificial nucleases or as artificial 
ribozyme, with the exclusion of the methods according to 

Art.52 (4)EPC. 
As medicinal products, compounds according to one 
of Claims 1 to 13, which can be used as antiviral agents, 

antitumor agents, antibiotics or antiparasitic agents or 
in any pathology where a gene is abnormally expressed 

either by mutation or by deregulation. 
</CLAIMS>
</TEXT>
</DOC>
